Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus R-GDP versus R-GDP in relapsed/refractory diffuse large B-cell lymphoma
2024-513616-95-00Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Selinexor + R-GDP with Placebo + R-GDP (2 arms). Primary endpoints: Overall response rate and Progression-free survival. Started Dec 2020; status: completed.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-513616-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513616-95-00.